Cleveland Clinic Cancer Center (Taussig) Outcomes
Prostate Cancer
Prostate Cancer
Biochemical Relapse Free Survival of Patients With Low-Risk Prostate Cancer by Treatment Typeᵃ (N = 2400)
1996-2021
| Treatment Group | 5 Years BRFS | 10 Years BRFS | 15 Years BRFS |
|---|---|---|---|
| External Beam Radiotherapy (N = 510) | 96.0% (350) | 85.7% (145) | 66.6% (26) |
| Low-Dose-Rate Brachytherapy (N = 1890) | 95.4% (902) | 86% (211) | 69.0% (30) |
EBRT= External Beam Radiotherapy, LDRBT = Low-Dose-Rate Brachytherapy, BRFS = Biochemical Relapse-Free Survival
ᵃNational Comprehensive Cancer Network (NCCN). Prostate Cancer. NCCN Clinical Practice Guidelines in Oncology. V.2.2007. Fort Washington, PA: NCCN; 2007.
Biochemical Relapse Free Survival of Patients With Favorable Intermediate-Risk Prostate Cancer by Treatment Typeᵃ (N = 1415)
1996-2021
| Treatment Group | 5 Years BRFS | 10 Years BRFS | 15 Years BRFS |
|---|---|---|---|
| External Beam Radiotherapy (N = 243) | 91.1% (144) | 77.3% (67) | 57.8% (4) |
| Low-Dose-Rate Brachytherapy (N = 1172) | 94.1% (390) | 84.1% (55) | 64.3% (11) |
EBRT= External Beam Radiotherapy, LDRBT = Low-Dose-Rate Brachytherapy, BRFS = Biochemical Relapse-Free Survival
ᵃNational Comprehensive Cancer Network (NCCN). Prostate Cancer. NCCN Clinical Practice Guidelines in Oncology. V.2.2007. Fort Washington, PA: NCCN; 2007.
Biochemical Relapse Free Survival of Patients With Unfavorable Intermediate Risk Prostate Cancer by Treatment Typeᵃ (N = 1709)
1996-2021
| Treatment Group | 5 Years BRFS | 10 Years BRFS | 15 Years BRFS |
|---|---|---|---|
| External Beam Radiotherapy (N = 423) | 79.7% (209) | 62.0% (81) | 42.1% (16) |
| Low-Dose-Rate Brachytherapy (N = 1283) | 81.9% (346) | 56.0% (49) | 41.5% (6) |
EBRT= External Beam Radiotherapy, LDRBT = Low-Dose-Rate Brachytherapy, BRFS = Biochemical Relapse-Free Survival
ᵃNational Comprehensive Cancer Network (NCCN). Prostate Cancer. NCCN Clinical Practice Guidelines in Oncology. V.2.2007. Fort Washington, PA: NCCN; 2007.
Biochemical Relapse Free Survival of Patients With High-Risk Prostate Cancer by Treatment Typeᵃ (N = 1066)
1996-2021
| Treatment Group | 5 Years BRFS | 10 Years BRFS | 15 Years BRFS |
|---|---|---|---|
| External Beam Radiotherapy (N = 646) | 71.6% (293) | 47.8% (98) | 36.5% (13) |
| Low-Dose-Rate Brachytherapy (N = 420) | 64.0% (115) | 34.3% (12) | NA (0) |
EBRT= External Beam Radiotherapy, LDRBT = Low-Dose-Rate Brachytherapy, BRFS = Biochemical Relapse-Free Survival
ᵃNational Comprehensive Cancer Network (NCCN). Prostate Cancer. NCCN Clinical Practice Guidelines in Oncology. V.2.2007. Fort Washington, PA: NCCN; 2007.
Cumulative Mortality Due to Prostate Cancer of Patients With Low-Risk Prostate Cancer by Treatment Typeᵃ (N= 2400)
1996-2021
| Treatment Group | 5 Years PCSM | 10 Years PCSM | 15 Years PCSM |
|---|---|---|---|
| External Beam Radiotherapy (N = 510) | 0.87% (409) | 1.87% (225) | 5.82% (65) |
| Low-Dose-Rate Brachytherapy (N = 1890) | 0.23% (1047) | 2.02% (317) | 3.87% (73) |
PCSM = Prostate Cancer Specific Mortality
ᵃNational Comprehensive Cancer Network (NCCN). Prostate Cancer. NCCN Clinical Practice Guidelines in Oncology. V.2.2007. Fort Washington, PA: NCCN; 2007.
Cumulative Mortality Due to Prostate Cancer of Patients With Favorable Intermediate Risk Prostate Cancer by Treatment Typeᵃ (N= 1415)
1996-2021
| Treatment Group | 5 Years PCSM | 10 Years PCSM | 15 Years PCSM |
|---|---|---|---|
| External Beam Radiotherapy (N = 243) | 1.00% (171) | 2.67% (107) | 8.18% (16) |
| Low-Dose-Rate Brachytherapy (N = 1172) | 0.19% (459) | 1.39% (92) | 2.92% (20) |
PCSM = Prostate Cancer Specific Mortality
ᵃNational Comprehensive Cancer Network (NCCN). Prostate Cancer. NCCN Clinical Practice Guidelines in Oncology. V.2.2007. Fort Washington, PA: NCCN; 2007.
Cumulative Mortality Due to Prostate Cancer of Patients With Unfavorable Intermediate Risk Prostate Cancer by Treatment Typeᵃ (N= 1709)
1996-2021
| Treatment Group | 5 Years PCSM | 10 Years PCSM | 15 Years PCSM |
|---|---|---|---|
| External Beam Radiotherapy (N = 423) | 3.36% (295) | 7.09% (165) | 10.45% (49) |
| Low-Dose-Rate Brachytherapy (N = 1283) | 0.55% (480) | 2.80% (121) | 7.56% (18) |
PCSM = Prostate Cancer Specific Mortality
ᵃNational Comprehensive Cancer Network (NCCN). Prostate Cancer. NCCN Clinical Practice Guidelines in Oncology. V.2.2007. Fort Washington, PA: NCCN; 2007.
Cumulative Mortality Due to Prostate Cancer of Patients With High-Risk Prostate Cancer by Treatment Typeᵃ (N= 1066)
1996-2021
| Treatment Group | 5 Years PCSM | 10 Years PCSM | 15 Years PCSM |
|---|---|---|---|
| External Beam Radiotherapy (N = 646) | 5.50% (447) | 13.76% (250) | 19.78% (68) |
| Low-Dose-Rate Brachytherapy (N = 420) | 3.86% (204) | 10.10% (46) | 13.10% (16) |
PCSM = Prostate Cancer Specific Mortality
ᵃNational Comprehensive Cancer Network (NCCN). Prostate Cancer. NCCN Clinical Practice Guidelines in Oncology. V.2.2007. Fort Washington, PA: NCCN; 2007.
